Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

PURPOSE: Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). PATIENTS AND METHODS: Patients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Galanis, Evanthia, Jaeckle, Kurt A., Maurer, Matthew J., Reid, Joel M., Ames, Matthew M., Hardwick, James S., Reilly, John F., Loboda, Andrey, Nebozhyn, Michael, Fantin, Valeria R., Richon, Victoria M., Scheithauer, Bernd, Giannini, Caterina, Flynn, Patrick J., Moore, Dennis F., Zwiebel, James, Buckner, Jan C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2669764/
https://ncbi.nlm.nih.gov/pubmed/19307505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.0694
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki